Skip to content
The BCI Briefing

Company profileNeuromodulation

Medtronic

Maker of the first deep brain stimulator authorised to adjust itself to the brain signals it records.

Location
Minneapolis, United States
Class
NeuromodulationA large medical-device maker, listed for one product line: deep brain stimulators that sense the brain's own signals and, since 2025, adjust stimulation to them. Nothing is decoded into a command, so it is not counted as a BCI company.Not counted among core BCI companies.
Funding stage
Public
Sources last checked
6 Oct 2026

What they are building

Sells Percept deep brain stimulators, which record local field potentials through the electrodes that deliver the therapy. BrainSense Adaptive DBS, approved by the FDA in February 2025 for Parkinson's disease, uses that recording to raise and lower stimulation as the signal changes.

Signal
Sensing DBS: Local field potentials out; electrical pulses inDBS: Continuous electrical pulses
Invasiveness
Invasive
Recording / stimulation
Recording and stimulation
Main use cases
Restore

Where they are clinically

Approved / cleared

Authorised by a regulator for a defined use. Always check the scope.

The approval covers adaptive stimulation for Parkinson's disease on Percept neurostimulators. It is a therapy that adapts to one recorded signal, not a BCI authorisation. Medtronic is legally based in Galway, Ireland, and run from Minneapolis, which is the place shown.

Access today

Available

Authorised and obtainable for a defined group of patients or users.

Shown in people
Adaptive stimulation in Parkinson's disease, tested in clinic and at home in the ADAPT-PD trial and approved by the FDA in February 2025.
Still an aim
Wider use of the recordings: the implants sense more than the approved algorithm acts on.
What stands in the way
The loop follows one recorded signal by a fixed rule. It adapts a therapy and does not decode what a person intends.

On record here: 0 peer-reviewed papers

  • 24 Feb 2025US FDA — Approval of adaptive deep brain stimulation. Stimulation that adjusts to local field potentials recorded by the same implant, for Parkinson's disease on Percept neurostimulators. A therapy that adapts to one signal; not a BCI authorisation.

Why this company matters

Medtronic matters to this field for precedent. Its sensing stimulators record from the brain in routine care, outside any study, and adaptive DBS is an authorised therapy in which an implant reads the brain and acts on what it reads with no clinician in the loop. The loop is simple: one signal, one rule. What it establishes is that a regulator will authorise a closed loop inside the brain, which every bidirectional BCI will depend on.

Key milestones

  1. 24 Feb 2025

    FDA approves BrainSense Adaptive DBS and the BrainSense Electrode Identifier for Parkinson's disease, on ADAPT-PD results in 68 patients.

    NeurologyLive

  2. 14 Dec 2020

    ADAPT-PD, the trial of the adaptive algorithm, begins. It enrols 85 participants at ten sites.

    ClinicalTrials.gov

IP and patents

Filings spread across 6 of the 11 layers, most often interface and electrodes (39 of 40 families) and stimulation (30).

40
patent families identified and counted as BCI
2005
earliest first filing among them
15
first filed since 2021; the latest years are incomplete
29 of 39
include a granted member, of those whose family record was read

Across the stack: families by layer

Themes, by number of families: electrodes and arrays (39), stimulation (30), wireless telemetry (22), peripheral interfaces (15), closed loop (15), packaging and hermeticity (11). A family can carry several.

Published in: United States (33), China (23), Australia (5), Japan (5), Austria (2), counted over the 39 families whose full record was read.

34 more families counted

Families found for Medtronic in the EPO’s worldwide database, grouped so that one invention counts once. A filing shows what a company sought to protect. It does not show that the technology was built, is in a product, or works in people, and themes are read from titles, abstracts and classes, not from the claims. How to read this

Competitive context

Sources

  1. 01

    FDA approves Medtronic's adaptive deep brain stimulation for Parkinson disease (opens in a new tab)

    Independent reportingNeurologyLive24 Feb 2025Checked against source 6 Oct 2026

    States the approval of adaptive DBS and the BrainSense Electrode Identifier on Percept neurostimulators, the sensing of local field potentials, and the ADAPT-PD trial in 68 patients.

  2. 02

    ClinicalTrials.gov NCT04547712: ADAPT-PD, adaptive DBS algorithm for personalised therapy in Parkinson's disease (opens in a new tab)

    Clinical registryClinicalTrials.govChecked against source 5 Oct 2026

    Sponsor MedtronicNeuro. Completed, 85 participants enrolled at ten sites; started 14 December 2020.

  3. 03

    Medtronic (opens in a new tab)

    Independent reportingWikipediaChecked against source 6 Oct 2026

    An encyclopaedia entry, used for one fact only: the legal seat in Galway, Ireland, and the operational headquarters in Minneapolis.